ABI 202
Alternative Names: ABI-202Latest Information Update: 07 Feb 2025
Price :
$50 *
At a glance
- Originator Avirmax Biopharma
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetic retinopathy
Most Recent Events
- 07 Feb 2025 Avirmax Biopharma plans to file an IND application for Proliferative diabetic retinopathy in Second half of 2026 (Avirmax Biopharma pipeline, February 2025).
- 06 Nov 2024 Preclinical trials in Diabetic retinopathy in USA (Intravitreous) before November 2024 (Avirmax Biopharma pipeline, November 2024)